Non-nucleoside structured compounds with antiviral activity-past 10 years (2010-2020)

Eur J Med Chem. 2022 Mar 5:231:114136. doi: 10.1016/j.ejmech.2022.114136. Epub 2022 Jan 19.

Abstract

Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of selected synthetic antiviral agents not associated to nucleosides developed against human viruses and introduced to preclinical and clinical trials as well as drugs approved for antiviral therapy over the last 10 years. The article describes for the first time the wide classification of such antiviral drugs and drug candidates and briefly summarizes the biological target and clinical applications of the compounds. The described compounds are arranged according to the antiviral mechanism of action. Knowledge of the drug's activity toward specific molecular targets may be the key to researching new antiviral compounds and repositioning drugs already approved for clinical use. The paper also briefly discusses the future directions of antiviral therapy. The described examples of antiviral compounds can be helpful for further drug development.

Keywords: Antiviral agents; Antiviral therapy; COVID-19; Clinical trials; Non-nucleosides.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Humans
  • Nucleosides* / pharmacology
  • Nucleosides* / therapeutic use
  • Pandemics
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Nucleosides